FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Para fines de investigación únicamente. Aviso completo →

Volver a Biblioteca de Investigación
PubMedSystematic ReviewSujetos Humanos

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Misra Saurav, Narayan Ravi Kant, Kaur Manmeet
Journal of basic and clinical physiology and pharmacology2025DOI: 10.1515/jbcpp-2025-0113
retatrutideglucagon receptor agonistGIP receptor agonistGLP-1 receptor agonist

Puntuación de Calidad

8/10

Citas

0

Sujetos

Humano

Análisis de Peptide Contacts

Study Design

Systematic reviews aggregate evidence across the entire body of published research, applying rigorous inclusion criteria to minimize selection bias. This methodology provides a comprehensive landscape view that individual studies cannot.

Our Assessment

Quality Assessment: 8/10 — This paper meets our highest quality thresholds. The methodology is well-designed, the statistical analysis is appropriate, and the conclusions are well-supported by the data presented. This is a reference-grade study for the peptides it covers.

Findings in Context

The results for retatrutide, glucagon receptor agonist, GIP receptor agonist, GLP-1 receptor agonist are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for retatrutide, glucagon receptor agonist, GIP receptor agonist, GLP-1 receptor agonist. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Encuentros Clave

Retatrutide, a triple-receptor agonist peptide, demonstrated significant weight loss and metabolic improvements in obese patients compared to placebo. The highest efficacy was observed with the 12 mg dosage.

Limitaciones

The review included only three clinical trials, which may limit generalizability. Additionally, gastrointestinal adverse effects were common among participants receiving retatrutide.

Cómo Interpretar esta Investigación

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análisis de Peptide Contacts

Highlighting the potential of retatrutide as a novel therapeutic option for obesity management, focusing on its mechanism of action and clinical trial outcomes.

retatrutideglucagon receptor agonistGIP receptor agonistGLP-1 receptor agonist

Retatrutide: A Promising New Tool in the Fight Against Obesity

Published: May 16, 2026 | Source: Journal of basic and clinical physiology and pharmacology (2025) | Category: retatrutide, glucagon receptor agonist, GIP receptor agonist, GLP-1 receptor agonist

Overview

A recent systematic review published in the Journal of Basic and Clinical Physiology and Pharmacology highlights the potential of retatrutide as a novel therapeutic option for obesity management. This peptide, which targets three key receptors involved in metabolism, has shown significant promise in clinical trials, offering hope to those struggling with weight-related health issues.

Study Background

Obesity is a growing public health concern linked to numerous serious conditions such as diabetes and cardiovascular disease. Traditional treatments often fall short due to limited efficacy or adverse side effects. Retatrutide, a triple-receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), offers an innovative approach by modulating multiple pathways involved in appetite regulation and metabolism. Researchers aimed to assess its safety and efficacy through a systematic review of available clinical trial data.

What the Research Found

The study reviewed three clinical trials involving 691 participants, with an average age of 54 years (335 men and 356 women). Participants were randomly assigned to receive either retatrutide or placebo. The highest efficacy was observed in patients receiving a weekly subcutaneous injection of 12 mg retatrutide, who experienced significant reductions in body weight, BMI, and waist circumference compared to the placebo group. Specifically, more participants achieved weight losses of ≥5%, 10%, 15%, and 20% with retatrutide treatment.

What This Means for Peptide Users

For individuals struggling with obesity, these findings suggest that retatrutide could be a valuable addition to existing therapeutic options. The peptide's ability to target multiple metabolic pathways offers a more comprehensive approach to weight management compared to single-receptor agonists currently available on the market. However, it is important to note that gastrointestinal side effects were common among participants receiving retatrutide, which may influence patient compliance and long-term use.

Limitations and Caveats

While the results are promising, several limitations must be acknowledged. The systematic review included only three clinical trials, which limits the generalizability of findings. Additionally, adverse effects such as gastrointestinal discomfort were frequently reported among participants receiving retatrutide, indicating that further research is needed to address these issues.

How This Compares to Previous Research

Previous studies on single-receptor agonists like GLP-1R have shown efficacy in weight management but often come with limitations regarding long-term safety and effectiveness. Retatrutide's multi-target approach represents a significant advancement, potentially offering better outcomes for patients struggling with obesity. However, the limited number of clinical trials included in this review means that more research is necessary to confirm these findings.

Our Analysis

At PeptideVault, we view this systematic review as an important step forward in understanding the potential benefits and risks associated with retatrutide therapy. The peptide's mechanism of action targeting multiple metabolic pathways presents a promising avenue for obesity management. However, the need for larger-scale clinical trials to validate these findings and address safety concerns remains paramount.

Key Takeaways

  • Retatrutide shows significant promise in reducing body weight and improving metabolic health in obese patients.
  • The 12 mg dosage appears most effective based on current data.
  • Gastrointestinal side effects are common, which may impact patient adherence to treatment.
  • More extensive clinical trials are necessary to confirm these findings and address safety concerns.

Original Source

Citation: Misra Saurav, Narayan Ravi Kant, Kaur Manmeet (2025). Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology. DOI: 10.1515/jbcpp-2025-0113

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue escrito por el equipo de investigación de Peptide Contacts para hacer hallazgos complejos accesibles a la comunidad de péptidos. Se anima a los lectores a revisar el paper fuente para metodología y datos completos. Para más sobre retatrutide, explore nuestros guias de investigación.

Cita

Misra Saurav, Narayan Ravi Kant, Kaur Manmeet. (2025). Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.. Journal of basic and clinical physiology and pharmacology. https://doi.org/10.1515/jbcpp-2025-0113

Ver texto completo en PubMed

Papers Relacionados

Explorar más

Este contenido se deriva de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.